Home › Companies › CHINOOK THERAPEUTICS INC. › 2023-2024

CHINOOK THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and CHINOOK THERAPEUTICS INC.’s Form 8-K, filed 2023-08-03 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 7Reported items
  • 206Asset managers
  • 826Fund votes
  • 2023-08-02Meeting date

Proxy season: 2023-2024

Explore CHINOOK THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by CHINOOK THERAPEUTICS INC.

These tallies are CHINOOK THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2023-08-03 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CHINOOK THERAPEUTICS INC. — official shareholder meeting results, meeting held 2023-08-02
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Merger Agreement Proposal 55,926,8259,09978,817 ---- Passed
NEO Compensation Proposal 31,494,21722,485,5382,034,986 ---- Passed

Source: CHINOOK THERAPEUTICS INC., Form 8-K, filed with the SEC on 2023-08-03 — read the filing on EDGAR.

How asset managers voted at the CHINOOK THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 206 asset managers that disclosed a CHINOOK THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CHINOOK THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To consider and vote upon the proposal to approve, on an advisory (non-binding) basis, certain compensation that may be paid or become payable to Chinook's named executive officers in connection with the Merger.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

0.3% fund support · no official result

AGAINST 99.7%

The 124 asset managers below cast 0.3% of the shares they voted on this item FOR (9,701,656 for, 4,495,219,018 against).

FOR: 9,701,656 (0.2%)AGAINST: 4,495,219,018 (99.8%)ABSTAIN: 76,226 (0.0%)
Largest asset managers voting on “To consider and vote upon the proposal to approve, on an advisory (non-binding) basis, certain compensation th” at CHINOOK THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
AQR Arbitrage LLC04,186,000,000 00Against
Janus Henderson0289,000,000 00Against
State Street4,611,931600 00For
BlackRock2,3404,009,948 00Against
Vanguard02,955,240 00Against
MUTUAL FUND SERIES TRUST1,927,0000 00For
SUVRETTA CAPITAL MANAGEMENT, LLC1,748,1410 00For
FRANKLIN ADVISERS INC01,268,649 00Against
Dimensional01,249,675 00Against
GEODE CAPITAL MANAGEMENT, LLC01,060,171 00Against
Fidelity01,036,479 00Against
Laurion Capital Management LP0768,670 00Against
Magnetar Financial LLC0732,629 00Against
AllianceBernstein0690,281 00Against
Nuveen0678,757 00Against
TIAA0676,645 00Against
FRANKLIN STRATEGIC SERIES0669,546 00Against
MERGER FUND454,3430 00For
Woodline Partners LP451,0260 00For
Hudson Bay Capital Management LP0417,012 00Against
Rock Springs Capital Management LP0396,280 00Against
MELLON INVESTMENTS Corp0295,153 00Against
Pentwater Capital Management LP0246,456 00Against
Vestal Point Capital, LP0239,261 00Against
DRIEHAUS CAPITAL MANAGEMENT LLC0211,616 00Against

Showing the 25 largest of 124 asset managers. See all 124 in the interactive database.

2. To consider and vote upon the proposal to adopt the Agreement and Plan of Merger, dated as of June 11, 2023 (which, as it may be amended from time to time, we refer to as the "Merger Agreement"), by and among Chinook Therapeutics, Inc., a Delaware corporation (the "Company") Novartis AG, a company organized under the laws of Switzerland ("Novartis"), and Cherry Merger Sub Inc., a Delaware corporat

EXTRAORDINARY TRANSACTIONSCompany result: Passed

Combines 8 wordings of this item as funds reported it.

99.9% Passed · of votes cast

FOR 99.9%
FOR: 55,926,825AGAINST: 9,099

CHINOOK THERAPEUTICS INC.’s own tally for this item (“Merger Agreement Proposal”): 55,926,825 for, 9,099 against — passed, per its Form 8-K filed 2023-08-03 (Item 5.07).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (16,945,851 for, 0 against).

FOR 99.5%
FOR: 16,945,851 (99.6%)ABSTAIN: 74,220 (0.4%)
Largest asset managers voting on “To consider and vote upon the proposal to adopt the Agreement and Plan of Merger, dated as of June 11, 2023 (w” at CHINOOK THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,857,9950 00For
BlackRock2,409,1000 00For
MUTUAL FUND SERIES TRUST1,927,0000 00For
State Street1,797,9440 00For
Federated Hermes1,232,5460 00For
Dimensional1,113,6210 00For
Fidelity1,033,2200 00For
TIAA676,6450 00For
FRANKLIN STRATEGIC SERIES669,5460 00For
MERGER FUND454,3430 00For
Charles Schwab375,2390 00For
Altium Capital Management LP305,0000 00For
NEXPOINT FUNDS I276,1760 00For
Equitable122,4390 74,2200For
Aberdeen150,8630 00For
Direxion Shares ETF Trust144,4820 00For
OLD WESTBURY FUNDS INC143,9350 00For
Northern Trust118,1650 00For
JPMorgan107,6480 00For
QUANTITATIVE MASTER SERIES LLC100,3640 00For
Lincoln Financial93,5610 00For
ProShares59,1000 00For
Jackson National54,5760 00For
ALPS ETF Trust49,1660 00For
Virtus47,9390 00For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

3. To consider and vote upon the proposal to adjourn the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve the proposal to adopt the Merger Agreement at the time of the Special Meeting.

CORPORATE GOVERNANCE

81% fund support · no official result

FOR 81%AGAINST 19%

The 68 asset managers below cast 81% of the shares they voted on this item FOR (12,147,537 for, 2,863,714 against).

FOR: 12,147,537 (80.5%)AGAINST: 2,863,714 (19.0%)ABSTAIN: 74,220 (0.5%)
Largest asset managers voting on “To consider and vote upon the proposal to adjourn the Special Meeting, if necessary or appropriate, to solicit” at CHINOOK THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard2,857,9950 00For
BlackRock2,409,1000 00For
State Street01,797,944 00Against
Federated Hermes1,232,5460 00For
Dimensional1,113,6210 00For
Fidelity24,3181,008,902 00Against
TIAA676,6450 00For
FRANKLIN STRATEGIC SERIES669,5460 00For
MERGER FUND454,3430 00For
Charles Schwab375,2390 00For
Altium Capital Management LP305,0000 00For
NEXPOINT FUNDS I276,1760 00For
Equitable122,4390 74,2200For
Aberdeen150,8630 00For
Direxion Shares ETF Trust144,4820 00For
OLD WESTBURY FUNDS INC143,9350 00For
Northern Trust118,1650 00For
JPMorgan107,6480 00For
QUANTITATIVE MASTER SERIES LLC100,3640 00For
Lincoln Financial45,80147,760 00Against
ProShares59,1000 00For
Jackson National54,5760 00For
ALPS ETF Trust49,1660 00For
Virtus47,9390 00For
Advisors' Inner Circle Fund III43,3660 00For

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

4. To consider and vote upon the proposal to approve, on an advisory (non-binding) basis, certain compensation that may be paid or become payable to the Company s named executive officers in connection with the Merger.

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

64% fund support · no official result

FOR 64%AGAINST 36%

The 41 asset managers below cast 64% of the shares they voted on this item FOR (8,651,485 for, 4,891,963 against).

FOR: 8,651,485 (63.9%)AGAINST: 4,891,963 (36.1%)NOT VOTED: 2,000 (0.0%)
Largest asset managers voting on “To consider and vote upon the proposal to approve, on an advisory (non-binding) basis, certain compensation th” at CHINOOK THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Samsara BioCapital, LLC5,161,8880 00For
Federated Hermes02,465,261 00Against
FARALLON CAPITAL MANAGEMENT LLC1,444,9800 00For
Man Group plc01,138,310 00Against
TIG Advisors, LLC856,3410 00For
Charles Schwab0750,478 00Against
Segantii Capital Management Ltd400,0000 00For
Altium Capital Management LP305,0000 00For
Saturn V Capital Management LP240,6550 00For
Nicholas Investment Partners, LP0206,206 00Against
KRYGER CAPITAL Ltd124,3540 00For
SEI075,532 00Against
NEW YORK STATE COMMON RETIREMENT FUND055,483 00Against
HARVEST MANAGEMENT LLC48,4790 00For
Advisors' Inner Circle Fund III043,366 00Against
BALYASNY ASSET MANAGEMENT L.P.043,038 00Against
WASHINGTON STATE INVESTMENT BOARD036,867 00Against
Equitable25,0000 00For
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM021,769 00Against
Gabelli19,0000 00For
Birchview Capital, LP15,0000 00For
Arizona State Retirement System012,946 00Against
Prudential/PGIM012,673 00Against
BANK OF AMERICA NA07,798 00Against
UNITED CAPITAL FINANCIAL ADVISORS, LLC07,600 00Against

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

5. To consider and vote upon the proposal to approve, on an advisory (non-binding) basis, certain compensation that may be paid or become payable to Company's named executive officers in connection with the Merger

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

71% fund support · no official result

FOR 49.0%AGAINST 20%ABSTAIN 31%

The 40 asset managers below cast 71% of the shares they voted on this item FOR (2,277,191 for, 913,044 against).

FOR: 2,277,191 (49.0%)AGAINST: 913,044 (19.7%)ABSTAIN: 1,455,202 (31.3%)
Largest asset managers voting on “To consider and vote upon the proposal to approve, on an advisory (non-binding) basis, certain compensation th” at CHINOOK THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BAKER BROS. ADVISORS LP00 1,455,2020Abstain
MPM BioImpact LLC1,003,4060 00For
Ensign Peak Advisors, Inc359,4800 00For
Affinity Asset Advisors, LLC321,0150 00For
NEXPOINT FUNDS I0276,176 00Against
Sand Grove Capital Management LLP249,4620 00For
BAILLIE GIFFORD & CO LTD0183,933 00Against
JPMorgan0167,151 00Against
Gabelli164,7500 00For
Northern Trust057,908 00Against
Jackson National38,93315,643 00For
Centiva Capital, LP050,938 00Against
Westchester Capital Management, LLC47,1220 00For
BAILLIE GIFFORD OVERSEAS LTD040,849 00Against
AltShares Trust30,1020 00For
WATER ISLAND CAPITAL LLC30,1020 00For
Exchange Place Advisors Trust029,400 00Against
John Hancock022,357 00Against
Bridge Builder Trust019,522 00Against
Baillie Gifford Investment Management (Europe) Ltd016,974 00Against
Polar Asset Management Partners Inc.15,0000 00For
Lincoln Financial011,032 00Against
PenderFund Capital Management Ltd.10,2400 00For
PNC BANK, NATIONAL ASSOCIATION06,400 00Against
Allianz06,176 00Against

Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.

6. Advisory Vote on Golden Parachutes

SECTION 14A SAY-ON-PAY VOTES

47.1% fund support · no official result

FOR 47.1%AGAINST 52.9%

The 5 asset managers below cast 47.1% of the shares they voted on this item FOR (134,110 for, 150,403 against).

FOR: 134,110 (47.1%)AGAINST: 150,403 (52.9%)
Largest asset managers voting on “Advisory Vote on Golden Parachutes” at CHINOOK THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ADAGE CAPITAL PARTNERS GP, L.L.C.134,1100 00For
JPMorgan0130,662 00Against
ALGERT GLOBAL LLC018,850 00Against
Desjardins Global Asset Management Inc.0881 00Against
TD ASSET MANAGEMENT INC010 00Against

7. To consider and vote upon the proposal to approve on an advisory (non-binding) basis, certain compensations that may be paid or become payable to the Company's named executive officers in connection with the Merger

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

99.9% Passed · of votes cast

FOR 99.9%
FOR: 55,926,825AGAINST: 9,099

CHINOOK THERAPEUTICS INC.’s own tally for this item (“Merger Agreement Proposal”): 55,926,825 for, 9,099 against — passed, per its Form 8-K filed 2023-08-03 (Item 5.07).

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 698 against).

AGAINST 100%
AGAINST: 698 (100.0%)
Largest asset managers voting on “To consider and vote upon the proposal to approve on an advisory (non-binding) basis, certain compensations th” at CHINOOK THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Orion Porfolio Solutions, LLC0349 00Against
Orion Portfolio Solutions, LLC0349 00Against

Largest CHINOOK THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of CHINOOK THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting.

Top CHINOOK THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager Shares voted
1AQR Arbitrage LLC 4,186,000,000
2Janus Henderson 289,000,000
3State Street 4,612,531
4BlackRock 4,012,288
5Vanguard 2,955,240
6MUTUAL FUND SERIES TRUST 1,927,000
7SUVRETTA CAPITAL MANAGEMENT, LLC 1,748,141
8FRANKLIN ADVISERS INC 1,268,649
9Dimensional 1,249,675
10GEODE CAPITAL MANAGEMENT, LLC 1,060,171

Shown as share counts, not percentages: no shares-outstanding figure has been matched to CHINOOK THERAPEUTICS INC. for the 2023-2024 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At CHINOOK THERAPEUTICS INC.'s shareholder meeting held 2023-08-02, in the 2023-2024 proxy season, 206 asset managers reported how they voted in their SEC Form N-PX filings, covering 826 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. CHINOOK THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To consider and vote upon the proposal to approve, on an advisory (non-binding) basis, certain… — the reporting funds cast 0.3% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

CHINOOK THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).